Techcloses in 5mo
FDA approves Retatrutide this year?
Retatrutide is a triple agonist hormone/peptide drug developed by Eli Lilly and currently in trial to treat obesity, fatty liver disease, type-2 diabetes, knee osteoarthritis, and more. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants a full or conditional approval for Eli Lilly’…
24h volume
$194
Total volume
$577.9K
Liquidity
$573
Markets
1
31 Dec 2026
ScienceFDATechdrugChinese PeptidesGLPEli Lilly
Probability over time
Loading…
Holders and activity
Loading holders…
Markets and probabilities
1 marketsHow to read
The percentage is the implied probability of the outcome, between 0% and 100%. For mutually-exclusive markets the sum trends to 100% (no vig). The ▲/▼ arrow shows the change over the selected window (1h/24h/7d/30d) in percentage points (pp). Click a market to see its top holders (with average entry price and position change) and the latest trades.